Crossmark

Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis—time to reconsider treatment guidelines? A case series and review of literature

Crossref DOI link: https://doi.org/10.1007/s10067-020-05519-0

Published Online: 2020-11-23

Published Print: 2021-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rocha, Francisco Airton Castro https://orcid.org/0000-0003-4370-3294
Pinto, Ana Carolina Matias Dinelly https://orcid.org/0000-0002-2411-6708
Lopes, Jailson Rodrigues https://orcid.org/0000-0002-6887-8659
Deodhar, Atul https://orcid.org/0000-0002-2130-1246
Funding

Funding for this research was provided by:

Conselho Nacional de Desenvolvimento Científico e Tecnológico (405661/2018-5; 308429/2018-4)
License Information

Text and Data Mining valid from 2020-11-23

Version of Record valid from 2020-11-23
More Information

Article History

Received: 13 August 2020

Revised: 17 November 2020

Accepted: 19 November 2020

First Online: 23 November 2020

Compliance with ethical standards

:

: FACR: Consulting, Advisory Boards: Aché, Abbott, BMS, Grunenthal, Janssen, Novartis, Pfizer, ZodiacACMDP and JRL: NoneAD: Consulting, Advisory Boards: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Glaxo Smith & Kline, Janssen, Novartis, Pfizer, UCBResearch Grants: AbbVie, Eli Lilly, Glaxo Smith & Kline, Novartis, Pfizer, UCB

Document is current

Any future updates will be listed below